Following on from information provided to NICE by the company in October 2019, the appraisal of Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 homozygous for the F508del mutation [ID1486] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1486 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 January 2023 | Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 homozygous for the F508del mutation [ID1486] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 07 October 2019 | Suspended. This appraisal was due to start at the end of September. However the company, Vertex Pharmaceuticals, has informed us that it will not be participating in the appraisal. As a consequence, we have now suspended this appraisal. Please monitor this webpage for further updates. |
| 22 August 2019 | Draft scope documents |
| 25 September 2018 - 23 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual